PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8831920-4	1996	Administration of the same dose of ciprofibrate, to approximately 3500 patients with type IIb combined hyperlipidaemia, had a marked cholesterol- and triglyceride-lowering effect, in addition to producing a decrease in LDL cholesterol and apo B, and an increase in apo A-I.	ciprofibrate	35-47	apolipoprotein A1	Homo sapiens	265-272	
10941600-0	2000	Changes in paraoxonase and apolipoprotein A-I, B, C-III and E in subjects with combined familiar hyperlipoproteinemia treated with ciprofibrate.	ciprofibrate	131-143	apolipoprotein A1	Homo sapiens	27-61	
10941600-5	2000	We found that ciprofibrate administration enhanced production of apoA-I and paraoxonase transport capacity.	ciprofibrate	14-26	apolipoprotein A1	Homo sapiens	65-71